Australia reports first Tamiflu-resistant H1N1 case

	Tweet

The first Australian case of swine flu resistant to Roche Holding AG’s antiviral drug Tamiflu was confirmed by the Western Australia state government on Friday.

“The 38-year-old Perth man, who has a weakened immune system, initially responded to the drug but developed a resistant strain of the virus when his illness relapsed,” the state’s Department of Health said in a statement.

There have been 13 cases of Tamiflu-resistant infections around the world, the statement said.

A Roche executive said on Monday that isolated cases of Tamiflu-resistant H1N1 pandemic flu were to be expected, in line with what has been seen in clinical studies.

“There is no evidence that the virus has spread to other people. None of the patient’s family or hospital staff caring for him have contracted the virus, and he has not been in contact with the wider community,” said the state’s Chief Health Officer Tarun Weeramanthri, adding that the case was a rare and isolated one.

The man remained in a critical condition in intensive care.

SYDNEY (Reuters)

RELATED STORIES:
New Jersey plans $380 mln for stem cell research   Obesity: understanding the UK epidemic   Deaths not linked to H1N1 vaccines: WHO   US government paying ever more health costs - report   Americans visit doctor, hospital more often   Flu vaccines for nursing home workers effective in reducing outbreaks: study   The Forgotten Patients: What Happens to Intensive Care Unit Survivors Five Years After Discharge?   U.S. Congress to examine steroid use in football   Short waits, long consults keep most patients very happy with their physicians   Africa must do more to fight TB   Hepatitis B program helps cut infant infections   Making health information technology more patient-centered

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]